What To Know
- “It is an exciting time to be at AngelMed as we expand the launch of The Guardian System for patients who are at high risk from a prior ACS event.
- Mike will be instrumental in our goals to accomplish key milestones in the launch of The Guardian as well as building a sales force for the future,”.
Mike Gillem will be responsible for the direction and management of all sales and marketing activities for The Guardian System, the company’s premier cardiac monitoring product. Mike brings more than 29 years of medical device experience in Cardiology and Orthopedics serving in various sales and sales leadership roles.
“We are excited to have Mike as part of the AngelMed executive team. Mike will be instrumental in our goals to accomplish key milestones in the launch of The Guardian as well as building a sales force for the future,” said Brad Snow, Chief Executive Officer of AngelMed. “Mike’s leadership and broad experience of launching disruptive technologies will be key to establishing a strong foundation, systems and processes with a scalability that exceeds expectations.”
Prior to joining AngelMed, Gillem served as Chief Commercial Officer for McGinley Orthopedics where he helped introduce new, innovative technology to orthopedic surgeons and hospitals globally. Gillem has also held several senior level positions bringing new products to the marketplace and driving clinical adoption. Most notably was his early involvement with Foxhollow Technologies. His field execution and management leadership resulted in an explosive revenue ramp from zero revenue to over $150M in revenue in under 2 years. Gillem received his Bachelor of Science degree from Purdue University.
“It is an exciting time to be at AngelMed as we expand the launch of The Guardian System for patients who are at high risk from a prior ACS event. I’m looking forward to leading these efforts as we build out a top tier commercial team to enhance the standard of care,” said Mike Gillem, Chief Commercial Officer of AngelMed.
About The Guardian System
The Guardian device is implanted subcutaneously by a cardiologist during a low-risk, outpatient surgical procedure. The Guardian’s proprietary algorithm uses machine learning to establish a patients baseline then continuously records the heart’s electrical activity, 24/7, detecting and alerting for heart attacks. The Guardian device provides a more effective diagnosis of a life-threatening event when compared to patient symptoms alone.1
References
Food and Drug Administration Website. Summary of Safety and Effectiveness Data. https://www.fda.gov/media/96475/download. Accessed October 26, 2021